erlotinib hydrochloride has been researched along with floxuridine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (floxuridine) | Trials (floxuridine) | Recent Studies (post-2010) (floxuridine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 3,556 | 323 | 280 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | floxuridine (IC50) |
|---|---|---|---|
| Thymidylate synthase | Mus musculus (house mouse) | 1.0862 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciccolini, J; Ferrero, JM; Fischel, JL; Formento, P; Milano, G | 1 |
1 other study(ies) available for erlotinib hydrochloride and floxuridine
| Article | Year |
|---|---|
Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Size; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Floxuridine; Humans; Male; Prostatic Neoplasms; Quinazolines; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |